共 30 条
[11]
Heney N.M., Ahmed S., Flanaghan M.J., Et al., Superficial bladder cancer: Progression and recurrence, J Urol, 130, pp. 1083-1086, (1983)
[12]
Kozmik Z., Sure U., Ruedi D., Et al., Deregulated expression of PAX5 in medulloblastoma, Proc Natl Acad Sci, 92, pp. 5709-5713, (1995)
[13]
Lamm D.L., Long-term results of intravesical therapy for superficial bladder cancer, Urol Clin North Am, 19, pp. 573-580, (1992)
[14]
Levine A.J., p53, the cellular gatekeeper for growth and division, Cell, 88, pp. 323-331, (1997)
[15]
Llopis J., Alcaraz A., Ribal M.J., Et al., p53 expression predicts progression and poor survival in T1 bladder tumours, Eur Urol, 37, pp. 644-653, (2000)
[16]
Maulbecker C.C., Gruss P., The oncogenic potential of Pax genes, EMBO J, 12, pp. 2361-2397, (1993)
[17]
Mc Carty Jr. K.S., Miller L.S., Cox E.B., Et al., Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies, Arch Pathol Lab Med, 109, pp. 716-721, (1985)
[18]
Nutt S.L., Thevenin C., Busslinger M., Essential functions of Pax-5 (BSAP) in pro-B cell development, Immunobiol, 198, pp. 227-235, (1997)
[19]
Orlow I., Lianes P., Lacombe L., Et al., Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors, Cancer Res, 54, pp. 2848-2851, (1994)
[20]
Reiher F., Ozer O., Pins M., Et al., p53 and microvessel density in primary resection specimens of superficial bladder cancer, J Urol, 167, pp. 1469-1474, (2002)